Loading
GH
Genesis Healthcare, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Whitman Arnold M, was filed 23 Nov 2015.
Genesis Healthcare, Inc.: what insiders have been doing
Every trade that managers of Genesis Healthcare, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Genesis Healthcare, Inc. has had no insider filing for more than a year; the last one goes back to 28 May 2021.
Our records for Genesis Healthcare, Inc. go back to 2007, with 124 purchases and 352 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
776
Thresholds
n/a
Buy Volume
€3M
124 ops. · all time
Sell Volume
€6M
352 ops. · all time
Since the insiders bought
- -28.3%Entry US$5.05 · Close at T+365 US$3.62
- -24.8%Entry US$4.39 · Close at T+365 US$3.30
- -24.8%Entry US$4.39 · Close at T+365 US$3.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$161.9M
Valuation
Beta1.21
Profitability & ownership
ROA-3.9%
% institutions0.0%
Last declaration on 28 May 2021
Declarations776 total
46,793 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001632417-21-000001:0
28,437 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001814811-21-000001:0
66,598 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001693042-21-000001:0
37,168 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001631386-21-000001:0
60,940 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001310088-21-000001:0
34,812 shares@ US$0.24100.0% of flowClass A Common StockSEC:0001631292-21-000001:0
1,335,565.5 shares@ US$0.4789Class A Common StockSEC:0001633878-20-000002:0
105,000 shares0Class A Common StockSEC:0001631292-20-000002:0
225,000 shares0Class A Common StockSEC:0001310088-20-000002:0
205,000 shares0Class A Common StockSEC:0001693042-20-000002:0
150,000 shares0Class A Common StockSEC:0001632417-20-000002:0
135,000 shares0Class A Common StockSEC:0001631386-20-000001:0
3,315 shares@ US$0.9550.0% of flowClass A Common StockSEC:0001631292-20-000002:1
6,671 shares@ US$0.9550.0% of flowClass A Common StockSEC:0001310088-20-000002:1
7,457 shares@ US$0.9550.0% of flowClass A Common StockSEC:0001693042-20-000002:1
5,313 shares@ US$0.9550.0% of flowClass A Common StockSEC:0001632417-20-000002:1
124,079 shares0Class A Common StockSEC:0001268641-20-000001:0
124,079 shares0Class A Common StockSEC:0001133713-20-000001:0
124,079 shares0Class A Common StockSEC:0001220410-20-000001:0
124,079 shares0Class A Common StockSEC:0001316576-20-000001:0
143,466 shares0Class A Common StockSEC:0001220405-20-000003:0
124,079 shares0Class A Common StockSEC:0001633878-20-000001:0
124,079 shares0Class A Common StockSEC:0001235869-20-000001:0
32,012 shares@ US$0.62Class A Common StockSEC:0001220407-20-000002:0
14,939 shares@ US$0.620.0% of flowClass A Common StockSEC:0001632417-20-000001:0
25 of 776 declarations
About Genesis Healthcare, Inc.
Genesis Healthcare, Inc. is a U.S.-based post-acute care operator listed on the NYSE/NASDAQ under ticker GEN. The company was created in 2003 through a spin-off from Genesis Health Ventures, although its roots go back to the mid-1980s, when Genesis Health Ventures was founded in 1985 with nine centers. Today, Genesis Healthcare is headquartered in Kennett Square, Pennsylvania, United States, and operates as a holding company with subsidiaries focused on skilled nursing, senior living communities, and rehabilitation services. Its corporate headquarters is located at 101 East State Street, Kennett Square, PA.
Genesis’s business model centers on the operation and support of long-term care and rehabilitation assets. The company provides skilled nursing services, post-hospital transitional care, short- and long-term rehabilitation, and a broader set of related offerings such as contract rehabilitation therapy, respiratory therapy, physician services, staffing services, and accountable care. From a reporting standpoint, Genesis organizes its activities around inpatient services, rehabilitation therapy services, and other related operations. This mix gives the company exposure to several parts of the care continuum, while also leaving it sensitive to reimbursement trends, labor pressure, regulatory oversight, and utilization patterns.
Read moreShow less
In competitive terms, Genesis remains one of the larger post-acute care platforms in the United States. Company disclosures indicate that it has nearly 200 centers and senior living communities across 17 states, while its rehabilitation therapy business serves roughly 1,400 locations across 43 states and the District of Columbia. That footprint provides meaningful operating scale and geographic diversification, but the sector is still highly competitive and structurally challenged by margin pressure, staffing costs, and dependence on government payment programs. For investors, the key debate is execution: occupancy, cost control, clinical quality, and the ability to adapt the portfolio over time.
Recent developments have been mostly operational and reputational. In 2025, Genesis highlighted third-party recognition for multiple affiliated skilled nursing centers, including 2025 AHCA/NCAL Bronze Quality Awards and, in December 2025, national recognition from U.S. News & World Report and Newsweek for 2026. These awards support the view that management is focusing on quality metrics and care standards. At the same time, Genesis remains a cyclical and highly regulated healthcare operator, so the investment case for GEN on the U.S.-listed NYSE/NASDAQ market should be assessed with caution, particularly given the sector’s sensitivity to reimbursement policy and operating leverage.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
